Lupin Foundation bags CRISIL's Highest VO 1A rating for Excellence in Social Responsibility
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Subscribe To Our Newsletter & Stay Updated